New formulation approaches for the leishmanicidal drug Miltefosine and for the olyene antibiotic Amphotericin B.

At the beginning of the investigations described in this thesis a new pharmaceutical dosage form of miltefosine called IMPAVIDO rea ched the market. It is the first oral dosage form based on a phospholipids-like molecule, which allows treating visceral leishmaniasis Currently IMPAVIDO is used in India to perform late stage pharmaceutical studies. The possibility of an oral leishmaniasis treatment can be considered as breakthroug. But in some cases, e.g. for patients with gastro-intestinal diseases, an intra venous application of a drug is necessary. Due to the chemical structure of miltefosine a direct application as a solution is not possible The molecular behavior of miltefosine would lead to a massive haemolysis if a solution of it would enter the bloodstreaom of a patient.